{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:22:54Z","timestamp":1695572574084},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"DOI":"10.1093\/ndt\/gfi097","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T00:24:46Z","timestamp":1126052686000},"page":"23-28","source":"Crossref","is-referenced-by-count":15,"title":["Current treatment options in secondary renal hyperparathyroidism"],"prefix":"10.1093","volume":"21","author":[{"given":"Helmut","family":"Reichel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,9,6]]},"reference":[{"key":"key\n\t\t\t\t20171012171443_BIB1","doi-asserted-by":"crossref","unstructured":"Block GA, Hulbert S, Levin NW, Port FK. Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis1998; 31: 607\u2013617","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"key\n\t\t\t\t20171012171443_BIB2","doi-asserted-by":"crossref","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca \u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol2001; 12: 2131\u20132138","DOI":"10.1681\/ASN.V12102131"},{"key":"key\n\t\t\t\t20171012171443_BIB3","doi-asserted-by":"crossref","unstructured":"Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension2001; 38: 938\u2013942","DOI":"10.1161\/hy1001.096358"},{"key":"key\n\t\t\t\t20171012171443_BIB4","doi-asserted-by":"crossref","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol2004; 15: 2208\u20132218","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"key\n\t\t\t\t20171012171443_BIB5","unstructured":"Reichel H, Dr\u00fceke T, Ritz E. Skeletal disorders. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DNS, Ritz E, Winearls C, eds. Oxford Textbook of Clinical Nephrology. 2nd edition, Oxford: Oxford University Press, 1997: 1954\u20131981"},{"key":"key\n\t\t\t\t20171012171443_BIB6","doi-asserted-by":"crossref","unstructured":"Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 42: 1\u2013201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"key\n\t\t\t\t20171012171443_BIB7","doi-asserted-by":"crossref","unstructured":"Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid mediated osseous abnormalities in uremia. J Clin Endocrinol Metab1992; 75: 145\u2013150","DOI":"10.1210\/jc.75.1.145"},{"key":"key\n\t\t\t\t20171012171443_BIB8","doi-asserted-by":"crossref","unstructured":"London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, deVernejoul MC. Arterial calcification and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol2004; 15: 1943\u20131951","DOI":"10.1097\/01.ASN.0000129337.50739.48"},{"key":"key\n\t\t\t\t20171012171443_BIB9","doi-asserted-by":"crossref","unstructured":"Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol2005; 16: 520\u2013528","DOI":"10.1681\/ASN.2004070602"},{"key":"key\n\t\t\t\t20171012171443_BIB10","doi-asserted-by":"crossref","unstructured":"Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int2005; 67: 1179\u20131187","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"key":"key\n\t\t\t\t20171012171443_BIB11","doi-asserted-by":"crossref","unstructured":"Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol2003; 14: 159\u2013168","DOI":"10.1097\/01.ASN.0000038685.95946.83"},{"key":"key\n\t\t\t\t20171012171443_BIB12","doi-asserted-by":"crossref","unstructured":"Berl T, Berns AS, Hufer WE et al. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med1978; 88: 774\u2013780","DOI":"10.7326\/0003-4819-88-6-774"},{"key":"key\n\t\t\t\t20171012171443_BIB13","doi-asserted-by":"crossref","unstructured":"Memmos DE, Eastwood JB, Talner LB et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed)1981; 282: 1919\u20131924","DOI":"10.1136\/bmj.282.6280.1919"},{"key":"key\n\t\t\t\t20171012171443_BIB14","doi-asserted-by":"crossref","unstructured":"Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of \u201csuppressed\u201d parathyroid function. Kidney Int1993; 44: 860\u2013866","DOI":"10.1038\/ki.1993.323"},{"key":"key\n\t\t\t\t20171012171443_BIB15","doi-asserted-by":"crossref","unstructured":"Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int1992; 42: 1191\u20131198","DOI":"10.1038\/ki.1992.404"},{"key":"key\n\t\t\t\t20171012171443_BIB16","doi-asserted-by":"crossref","unstructured":"Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int1994; 45: 1710\u20131721","DOI":"10.1038\/ki.1994.223"},{"key":"key\n\t\t\t\t20171012171443_BIB17","doi-asserted-by":"crossref","unstructured":"Norman PE, Powell JT. Vitamin D shedding light on the development of disease in peripheral arteries. Arteriosler Thromb Vasc Biol2005; 25: 39\u201346","DOI":"10.1161\/01.ATV.0000148450.56697.4a"},{"key":"key\n\t\t\t\t20171012171443_BIB18","doi-asserted-by":"crossref","unstructured":"Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis2002; 39: 1270\u20131277","DOI":"10.1053\/ajkd.2002.33401"},{"key":"key\n\t\t\t\t20171012171443_BIB19","doi-asserted-by":"crossref","unstructured":"Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol2000; 11: 2088\u20132094","DOI":"10.1681\/ASN.V11112088"},{"key":"key\n\t\t\t\t20171012171443_BIB20","doi-asserted-by":"crossref","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int2003; 63: 1483\u20131490","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"key\n\t\t\t\t20171012171443_BIB21","doi-asserted-by":"crossref","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med2003; 349: 446\u2013456","DOI":"10.1056\/NEJMoa022536"},{"key":"key\n\t\t\t\t20171012171443_BIB22","doi-asserted-by":"crossref","unstructured":"Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant2004; 19: 1174\u20131181","DOI":"10.1093\/ndt\/gfh123"},{"key":"key\n\t\t\t\t20171012171443_BIB23","doi-asserted-by":"crossref","unstructured":"Drueke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med2003; 349: 496\u2013499","DOI":"10.1056\/NEJMe038104"},{"key":"key\n\t\t\t\t20171012171443_BIB24","doi-asserted-by":"crossref","unstructured":"Frazao JM, Elangovan L, Maung HM et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis2000; 36: 550\u2013561","DOI":"10.1053\/ajkd.2000.16193"},{"key":"key\n\t\t\t\t20171012171443_BIB25","doi-asserted-by":"crossref","unstructured":"Hayashi M, Tsuchiya Y, Itaya Y et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients in chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant2004; 19: 2067\u20132073","DOI":"10.1093\/ndt\/gfh329"},{"key":"key\n\t\t\t\t20171012171443_BIB26","doi-asserted-by":"crossref","unstructured":"Drueke TB. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrol Dial Transplant2002; 17 [Suppl 11]: 20\u201322","DOI":"10.1093\/ndt\/17.suppl_11.20"},{"key":"key\n\t\t\t\t20171012171443_BIB27","doi-asserted-by":"crossref","unstructured":"Bayard F, Bec P, Ton That H, Louvet JP. Plasma 25-hydroxycholecalciferol in chronic renal failure. Eur J Clin Invest1973; 3: 447\u2013450","DOI":"10.1111\/j.1365-2362.1973.tb02213.x"},{"key":"key\n\t\t\t\t20171012171443_BIB28","doi-asserted-by":"crossref","unstructured":"Ghazali A, Fardellone P, Pruna A et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int1999; 55: 2169\u20132177","DOI":"10.1046\/j.1523-1755.1999.00480.x"},{"key":"key\n\t\t\t\t20171012171443_BIB29","doi-asserted-by":"crossref","unstructured":"Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int1988; 34: 368\u2013375","DOI":"10.1038\/ki.1988.190"},{"key":"key\n\t\t\t\t20171012171443_BIB30","unstructured":"Ott SM. Aluminium-related osteomalacia. Int J Artif Organs1983; 6: 173\u2013175"},{"key":"key\n\t\t\t\t20171012171443_BIB31","doi-asserted-by":"crossref","unstructured":"Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis1991; 17: 544\u2013550","DOI":"10.1016\/S0272-6386(12)80496-3"},{"key":"key\n\t\t\t\t20171012171443_BIB32","unstructured":"Hercz G, Kraut JA, Andress DA et al. Use of calcium carbonate as a phopsphate binder in dialysis patients. Miner Electrolyte Metab1986; 12: 314\u2013319"},{"key":"key\n\t\t\t\t20171012171443_BIB33","doi-asserted-by":"crossref","unstructured":"Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JSl. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int1989; 36: 690\u2013695","DOI":"10.1038\/ki.1989.247"},{"key":"key\n\t\t\t\t20171012171443_BIB34","doi-asserted-by":"crossref","unstructured":"Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med2000; 342: 1478\u20131483","DOI":"10.1056\/NEJM200005183422003"},{"key":"key\n\t\t\t\t20171012171443_BIB35","doi-asserted-by":"crossref","unstructured":"Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant2000; 15: 1014\u20131021","DOI":"10.1093\/ndt\/15.7.1014"},{"key":"key\n\t\t\t\t20171012171443_BIB36","doi-asserted-by":"crossref","unstructured":"Locatelli F, Cannata A, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant2002; 17: 723\u2013731","DOI":"10.1093\/ndt\/17.5.723"},{"key":"key\n\t\t\t\t20171012171443_BIB37","doi-asserted-by":"crossref","unstructured":"Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium\u2009\u00d7 phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant1999; 14: 2907\u20132914","DOI":"10.1093\/ndt\/14.12.2907"},{"key":"key\n\t\t\t\t20171012171443_BIB38","doi-asserted-by":"crossref","unstructured":"Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int2002; 62: 245\u2013252","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"key\n\t\t\t\t20171012171443_BIB39","doi-asserted-by":"crossref","unstructured":"Coladonato JA, Ritz E. SHPT and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Adv Ren Replace Ther2002; 9: 193\u2013199","DOI":"10.1053\/jarr.2002.34842"},{"key":"key\n\t\t\t\t20171012171443_BIB40","doi-asserted-by":"crossref","unstructured":"Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE study). Kidney Int2004; 65: 1914\u20131926","DOI":"10.1111\/j.1523-1755.2004.00590.x"},{"key":"key\n\t\t\t\t20171012171443_BIB41","doi-asserted-by":"crossref","unstructured":"Hutchison AJ, Speake M, Al Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant2004; 19: 1902\u20131906","DOI":"10.1093\/ndt\/gfh282"},{"key":"key\n\t\t\t\t20171012171443_BIB42","doi-asserted-by":"crossref","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomised, comparative trial versus calcium carbonate. Nephron Clin Pract2005; 100: c8\u2013c19","DOI":"10.1159\/000084653"},{"key":"key\n\t\t\t\t20171012171443_BIB43","doi-asserted-by":"crossref","unstructured":"Behets GJ, Dams G, Vercauteren SR et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol2004; 15: 2219\u20132228","DOI":"10.1097\/01.ASN.0000133022.32912.95"},{"key":"key\n\t\t\t\t20171012171443_BIB44","doi-asserted-by":"crossref","unstructured":"Lacour B, Lucas A, Auchere D et al Chronic renal failure is associated with increased tissue deposition of lanthanum after 28 day oral administration. Kidney Int2005; 67: 1062\u20131069","DOI":"10.1111\/j.1523-1755.2005.00171.x"},{"key":"key\n\t\t\t\t20171012171443_BIB45","unstructured":"Webster I, Gill M. Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients. EDTA, Lisbon, Portugal, 2004; Abstract SP268"},{"key":"key\n\t\t\t\t20171012171443_BIB46","doi-asserted-by":"crossref","unstructured":"Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant2002; 17: 204\u2013207","DOI":"10.1093\/ndt\/17.2.204"},{"key":"key\n\t\t\t\t20171012171443_BIB47","doi-asserted-by":"crossref","unstructured":"Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol2003; 14: 575\u2013583","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"key\n\t\t\t\t20171012171443_BIB48","doi-asserted-by":"crossref","unstructured":"Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium\u2009\u00d7 phosphorus in secondary hyperparathyroidism. Kidney Int2003; 63: 248\u2013254","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"key\n\t\t\t\t20171012171443_BIB49","doi-asserted-by":"crossref","unstructured":"Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med2004; 350: 1516\u20131525","DOI":"10.1056\/NEJMoa031633"},{"key":"key\n\t\t\t\t20171012171443_BIB50","doi-asserted-by":"crossref","unstructured":"Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K\/DOQI\u2122 bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int2005; 67: 760\u2013771","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"key\n\t\t\t\t20171012171443_BIB51","unstructured":"Cunningham J, Urena P, Reichel H et al. Long-term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end-stage renal diesease (ESRD). XLII Congress of the ERA-EDTA, 2005; Abstract"},{"key":"key\n\t\t\t\t20171012171443_BIB52","doi-asserted-by":"crossref","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow G. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int2005; in press.","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"key\n\t\t\t\t20171012171443_BIB53","unstructured":"Chertow GM, Corpier C, Zeig S et al. Preliminary results from TARGET: Treatment Strategies to achieve recommended K\/DOQI\u2122 goals in ESRD patients on Cinacalcet. J Am Soc Nephrol2004; 15: 863A"},{"key":"key\n\t\t\t\t20171012171443_BIB54","doi-asserted-by":"crossref","unstructured":"Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyoidism. Nephrol Dial Transplant2004; 19 [Suppl 5]: v9\u2013v14","DOI":"10.1093\/ndt\/gfh1050"},{"key":"key\n\t\t\t\t20171012171443_BIB55","unstructured":"Cannata-Andia JB, Drueke TB, Cunningham J et al. Clinical algorithms on renal osteodystrophy. Nephrol Dial Transplant2000; 15 [Suppl 5]: 40\u201357"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/1\/23\/5148260\/gfi097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T01:50:57Z","timestamp":1626486657000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/1\/23\/1818935\/Current-treatment-options-in-secondary-renal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,9,6]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi097","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,1]]},"published":{"date-parts":[[2005,9,6]]}}}